Beam Therapeutics Inc (BEAM)

$25.24

-0.82

(-3.15%)

Market is closed - opens 7 PM, 14 Jun 2024

Insights on Beam Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 316.19M → 7.41M (in $), with an average decrease of 97.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 142.79M → -98.66M (in $), with an average decrease of 169.1% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 81.8% return, outperforming this stock by 104.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 239.3% return, outperforming this stock by 309.9%

Performance

  • $25.05
    $26.48
    $25.24
    downward going graph

    0.75%

    Downside

    Day's Volatility :5.38%

    Upside

    4.66%

    downward going graph
  • $16.95
    $49.50
    $25.24
    downward going graph

    32.84%

    Downside

    52 Weeks Volatility :65.76%

    Upside

    49.01%

    downward going graph

Returns

PeriodBeam Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-30.26%
-0.3%
0.0%
6 Months
-7.85%
7.4%
0.0%
1 Year
-22.92%
11.0%
0.0%
3 Years
-71.66%
17.3%
-24.3%

Highlights

Market Capitalization
2.0B
Book Value
$11.58
Earnings Per Share (EPS)
-1.6
Wall Street Target Price
48.67
Profit Margin
-37.33%
Operating Margin TTM
-1405.29%
Return On Assets TTM
-8.44%
Return On Equity TTM
-16.09%
Revenue TTM
360.9M
Revenue Per Share TTM
4.54
Quarterly Revenue Growth YOY
-69.39999999999999%
Gross Profit TTM
-250.7M
EBITDA
-160.9M
Diluted Eps TTM
-1.6
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-4.75
EPS Estimate Next Year
-4.76
EPS Estimate Current Quarter
-1.42
EPS Estimate Next Quarter
-1.38

Analyst Recommendation

Buy
    61%Buy
    38%Hold
    0
    0%Sell
Based on 21 Wall street analysts offering stock ratings for Beam Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 21 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
13
Hold
8
8
8
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 92.83%

Current $25.24
Target $48.67

Technicals Summary

Sell

Neutral

Buy

Beam Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Beam Therapeutics Inc
Beam Therapeutics Inc
8.49%
-7.85%
-22.92%
-71.66%
-66.48%
Moderna, Inc.
Moderna, Inc.
17.55%
87.94%
15.42%
-28.78%
814.11%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.19%
17.3%
33.92%
94.36%
234.29%
Novo Nordisk A/s
Novo Nordisk A/s
8.19%
44.85%
81.77%
239.36%
454.2%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
10.67%
17.46%
39.08%
144.25%
181.72%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Beam Therapeutics Inc
Beam Therapeutics Inc
NA
NA
NA
-4.75
-0.16
-0.08
NA
11.58
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.82
29.82
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.58
49.58
2.36
3.48
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.23
31.23
0.53
17.08
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Beam Therapeutics Inc
Beam Therapeutics Inc
Buy
$2.0B
-66.48%
NA
-37.33%
Moderna, Inc.
Moderna, Inc.
Buy
$56.6B
814.11%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$111.3B
234.29%
29.82
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$636.1B
454.2%
49.58
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$124.3B
181.72%
31.23
39.46%

Institutional Holdings

  • ARK Investment Management LLC

    9.94%
  • Vanguard Group Inc

    9.21%
  • BlackRock Inc

    8.15%
  • FMR Inc

    5.95%
  • Farallon Capital Management, L.L.C.

    5.48%
  • Morgan Stanley - Brokerage Accounts

    5.01%

Corporate Announcements

  • Beam Therapeutics Inc Earnings

    Beam Therapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

beam therapeutics is developing precision genetic medicines for serious diseases. co-founded by scientific pioneers known for advancing crispr gene editing, we’re the first company to pursue development of new therapies using crispr base editing technology. we aim to use these technologies to generate a broad pipeline of precision genetic medicines that repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. who we are beam is creating precision genetic medicines through base editing why we do it our dream is to provide life-long cures for patients suffering from serious diseases who we are and how we work together the beam team:  a community of fearless innovators  rigorous and honest in our research  listening with open minds  committed to each other

Organization
Beam Therapeutics Inc
Employees
346
CEO
Mr. John M. Evans M.B.A.
Industry
Health Technology

FAQs